AXIOS August 22, 2024
Tina Reed

The Food and Drug Administration approved new formulations of both Moderna and the Pfizer-BioNTech COVID-19 vaccines on Thursday.

Why it matters: The approval comes as the number of COVID infections grows in more than two dozen states and respiratory virus season fast approaches.

State of play: CDC advisers in June recommended that people 6 months of age and older receive updated COVID-19 vaccines when they become available this fall.

  • The new vaccine doses are tailored to the KP.2 strain — a descendant of the highly contagious JN.1 variant. The KP variants account for almost 70% of all current cases in the U.S.
  • Officials said individuals who receive one of these updated...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, FDA, Govt Agencies, Healthcare System, Patient / Consumer, Pharma / Biotech, Provider, Public Health / COVID
Related Articles:
FDA warns GLP-1 compounder over safety rules
GLP-1 drug approvals: A breakdown
Rethinking FDA’s Accelerated Approval Pathway: New Draft Guidances and Implications for Drug Companies
FDA approves Novo Nordisk's Ozempic to treat chronic kidney disease in those with diabetes, expanding its use
Certainty vs. speed: How do patients feel about the tradeoff for new cancer drugs?

Share This Article